
Proceedings Paper
Pentamethylpyrromethene boron difluoride complexes in human ovarian cancer photodynamic therapyFormat | Member Price | Non-Member Price |
---|---|---|
$17.00 | $21.00 |
Paper Abstract
Quasiaromatic heterocycles (QAM) such as substituted
1 , 3 , 5 , 7 , 8-pentamethylpyrromethene boron difluorides (PMP-BF2)
and - (dimethoxyphosphinylmethyl, methyl) bimane have
been evaluated for their abilities to produce cellular
toxicities when used in photodynamic therapy (PDT) for
ovarian cancer. The most active QAH tested to date has been
the disodiuxn salt of PMP-2,6-disulfonate--BF2 (PMPDS-BF2).
Human ovarian cancer cells from fifteen different patients
have been grown in culture. Cells were obtained from biopsy
material and grown in RPMI medium with 10% FBA plus
penicillin and streptomycin. Cells were harvested and as
single cell suspensions exposed to PMP-BF2 complexes or
bimanes in concentrations of 0.004-0.4 ug/106 cells/ml of
medium. Initially the cells were exposed to the chemicals
for 30 minutes in a 5% CO2 incubator (37°C) with gentle
shaking. The cells were washed with plain RPMI medium, then
resuspended in the enriched RPMI medium and exposed to a
sunlamp for 10-20 minutes. Cells were then allowed to grow
in an soft agar culture media at 37°C (5% C02) for 14 days.
When compared to controls (only light or only chemicals)
there was 100% inhibition of all cellular growth for PMPDSBF2
at the 0.4 ug/mi concentrations. There was variations in
concentrations of the chemical needed to produce 100%
inhibition when the 15 different ovarian cancer cell
specimens were compared at all concentrations.
PMP-BF2 complexes are characterized by extremely high
extinction coefficients, superior laser activity and little
if any triplet-triplet absorption. The biamanes share these
properties however are less active in ovarian cancer cell
The lasing properties of PMP-BF2, and bimanes will be
compared to their PDT effectiveness.
Paper Details
Date Published: 1 July 1990
PDF: 13 pages
Proc. SPIE 1203, Photodynamic Therapy: Mechanisms II, (1 July 1990); doi: 10.1117/12.17671
Published in SPIE Proceedings Vol. 1203:
Photodynamic Therapy: Mechanisms II
Thomas J. Dougherty, Editor(s)
PDF: 13 pages
Proc. SPIE 1203, Photodynamic Therapy: Mechanisms II, (1 July 1990); doi: 10.1117/12.17671
Show Author Affiliations
Lee Roy Morgan, Dekk-Tec, Inc., King Foundation, and Univ. of New Orleans (United States)
Aulena Chaudhuri, Dekk-Tec, Inc., King Foundation, and Univ. of New Orleans (United States)
Laura E. Gillen, Dekk-Tec, Inc. and King Foundation (United States)
Aulena Chaudhuri, Dekk-Tec, Inc., King Foundation, and Univ. of New Orleans (United States)
Laura E. Gillen, Dekk-Tec, Inc. and King Foundation (United States)
Joseph H. Boyer, Univ. of New Orleans (United States)
Lionel T. Wolford, Univ. of New Orleans (United States)
Lionel T. Wolford, Univ. of New Orleans (United States)
Published in SPIE Proceedings Vol. 1203:
Photodynamic Therapy: Mechanisms II
Thomas J. Dougherty, Editor(s)
© SPIE. Terms of Use
